Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus NATURETIN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus NATURETIN 5.
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE vs NATURETIN-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, decreasing sodium and water reabsorption and reducing intravascular volume and blood pressure.
Initial dose: 1 tablet (candesartan cilexetil 16 mg / hydrochlorothiazide 12.5 mg) orally once daily; titrate based on response to maximum dose of 32 mg/25 mg once daily.
5 mg orally once daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal); Hydrochlorothiazide: 6–15 hours (terminal). Both support once-daily dosing.
Terminal elimination half-life is approximately 18-24 hours; clinically, this supports once-daily dosing and requires renal function monitoring.
Candesartan: 33% renal, 67% biliary/fecal. Hydrochlorothiazide: ≥95% renal (unchanged).
Primarily renal (70-80% as unchanged drug); the remainder (20-30%) is eliminated via biliary/fecal routes.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic